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Comparative Effectiveness Research (CER) 
and Evidence-Based Medicine (EBM) is at 
the heart of many transformative changes in 
health care, driven in part by the Affordable 
Care Act (ACA). Robert W. Dubois, MD, 
PhD, Chief Science Officer at the National 
Pharmaceutical Council, offered a compelling 
and succinct overview of CER and EBM at a 
Forum this past spring. 
The National Pharmaceutical Council (NPC) 
is a health policy research organization 
focused on the advancement of good evidence 
and science, and fostering medical innovation 
within the United States.  Dr. Dubois oversees 
NPC’s research on policies related to CER 
and health outcomes. Throughout his career, 
Dr. Dubois’ primary interest has centered 
on defining “what works” in health care and 
finding ways for that evidence to inform health 
care decision making. He is a recognized 
expert in defining best practices, disease 
management and appropriateness of care. 
Dr. Dubois began his presentation by 
explaining that CER is not exactly new, 
but that it is related to EBM and decision 
making; in other words, it is important that 
it is used to examine and improve clinical 
practice.  He refers to Eddy’s  model of 
thought process that describes evidence, 
scientific judgments and value judgments, 
and how these influence decisions. 1 
Dubois described EBM as a general concept of 
using evidence to apply to a clinical decision, 
whereas CER is a more patient-focused 
strategy that compares alternative approaches 
to management.  Dubois provides an easy 
approach to the thought process around CER 
by using these questions: What works when? 
For whom? And Under what circumstances?  
Adding to this, he outlines characteristics 
that are critical to CER and decision making:  
delivery of the right care, to the right patient, at 
the right time, in the most appropriate setting.  
He states that we have to make this easy to do 
and embedded in how we make health choices. 
Although there is overlap between CER, 
EBM and Health Technology Assessment 
(HTA), Dubois identified differences: CER 
is primarily a research activity to answer 
certain questions; EBM is focused on 
the application; and HTA is centered on 
assessment and cost-effectiveness. 
Dubois discussed two major motivators 
illustrating the need for CER.  First, patients 
face many alternative therapeutic options to 
manage their conditions, and comparative 
evidence is often not available.  Second, the 
complex and chronic conditions characteristic of 
the baby boomer population demand different 
and effective health strategies, especially as we 
face concerns about rising health care costs. 
Dubois went on to discuss the relationship 
between CER and medications. He described 
the challenges of population vs. individual 
results. For example, efficacy data on certain 
medications may not apply to individuals. 
Posing the question, “Will access to 
medications be constrained?” Dubois states 
that this could vary in different states. This 
is  an example of how difficult it can be to 
translate CER into policy choices.  
For more information on the National 
Pharmaceutical Council visit:  
http://www.npcnow.org/
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In this workshop, Dr. Dubois continued to discuss CER through a stimulating discussion of heterogeneity and the importance of 
finding a balance between CER results at the population level and when that may be applied appropriately to the individual.  
Dubois identified key factors to be taken into account when considering variation in individual treatment response as: likelihood 
of response to similar treatments; clinical consequences of delaying optimal treatment; underlying patient diversity; and patient 
preferences. These factors influence and affect the higher risk and clinical impact of heterogeneity. Dubois used the example of 
treatments for depression and multiple sclerosis to show how difficult it is to provide a population-based framework for treatment.  
Individual differences and patient preferences are significant factors in treatment strategies. 
The audience had the opportunity to ask a number of questions, and the interactive session also addressed issues of payments for 
tests, companion diagnostics, and value-based purchasing.  Dr. Dubois concluded by discussing some of the new payment changes to 
providers, where they will be accountable for both the economics of care, and quality performance.  
